Switch theme
Sign up to access all valuation multiples
ToolGen Inc is a biotechnology company, which focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified, gRNA/Cas9, and recombinant Cas9 protein, which offers ready-to-use reagents for genome engineering experiments. The company also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ToolGen has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, ToolGen achieved revenue of $0.6M and an EBITDA of $7.3M.
ToolGen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ToolGen valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.8M | $0.6M | XXX | XXX | XXX |
| Gross Profit | $0.4M | $0.6M | XXX | XXX | XXX |
| Gross Margin | 51% | 105% | XXX | XXX | XXX |
| EBITDA | -$27.5M | $7.3M | XXX | XXX | XXX |
| EBITDA Margin | -3659% | 1195% | XXX | XXX | XXX |
| Net Profit | -$12.4M | -$28.8M | XXX | XXX | XXX |
| Net Margin | -1647% | -4752% | XXX | XXX | XXX |
| Net Debt | n/a | $17.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ToolGen's stock price is KRW 32550 (or $22).
ToolGen has current market cap of KRW 259B (or $176M), and EV of KRW 224B (or $152M).
See ToolGen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $152M | $176M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ToolGen has market cap of $176M and EV of $152M.
ToolGen's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate ToolGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ToolGen and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $152M | XXX | XXX | XXX |
| EV/Revenue | 251.0x | XXX | XXX | XXX |
| EV/EBITDA | 21.0x | XXX | XXX | XXX |
| P/E | 41.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -13.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpToolGen's NTM/LTM revenue growth is n/a
ToolGen's revenue per employee for the last fiscal year averaged $28K, while opex per employee averaged $0.7M for the same period.
Over next 12 months, ToolGen's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ToolGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ToolGen and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -19% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 1195% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -126% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $28K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 991% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 50% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 768% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2522% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| Oryzon Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ToolGen acquired XXX companies to date.
Last acquisition by ToolGen was XXXXXXXX, XXXXX XXXXX XXXXXX . ToolGen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was ToolGen founded? | ToolGen was founded in 1999. |
| Where is ToolGen headquartered? | ToolGen is headquartered in South Korea. |
| How many employees does ToolGen have? | As of today, ToolGen has 22 employees. |
| Is ToolGen publicy listed? | Yes, ToolGen is a public company listed on KRX. |
| What is the stock symbol of ToolGen? | ToolGen trades under 199800 ticker. |
| When did ToolGen go public? | ToolGen went public in 2014. |
| Who are competitors of ToolGen? | Similar companies to ToolGen include e.g. EZZ Life Science, Epigenomics, 4basebio, Genus. |
| What is the current market cap of ToolGen? | ToolGen's current market cap is $176M |
| What is the current revenue growth of ToolGen? | ToolGen revenue growth between 2023 and 2024 was -19%. |
| Is ToolGen profitable? | Yes, ToolGen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
